India unrelenting over alleged lax IPR; may drag the USA to the WTO

28 April 2014

A clarion call has been sounded by Indian government officials, who are unwilling to buckle under pressure from drug multinationals on intellectual property laws. Dismissing US charges over inept intellectual property rights (IPR) in the country, officials have maintained that, if push comes to shove, India would not hesitate to drag the USA to the World Trade Organization’s dispute resolution mechanism, reports The Pharma Letter's India correspondent.

In a closed door meeting called for by Cabinet Secretary Ajit Seth, secretaries of five government departments thrashed out the different ways India would address some of the alleged IPR delinquent issues being raised by certain US drug companies.

Besides Mr Seth, Health Secretary Lov Kumar Verma, Department of Pharmaceuticals Secretary Aradhana Johri, Department of Industrial Policy and Promotion Secretary (DIPP) Amitabh Kant, Commerce Secretary Rajeev Kher, and Foreign Secretary Sujatha Singh had gathered to discuss a probable rollback of some of India's IPR laws. The meeting was called on the insistence of Foreign Secretary Sujatha Singh and S Jaishankar, India’s Ambassador to the USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical